Price Alert

Corcept Therapeutics (CORT)

NASDAQ: CORT · Real-Time Price · USD

71.83

-0.17 (-0.24%)

At close: Aug 15, 2025, 2:56 PM

Corcept Therapeutics Statistics

Share Statistics

Corcept Therapeutics has 105.37M shares outstanding. The number of shares has increased by 1.49% in one year.

Shares Outstanding	105.37M
Shares Change (YoY)	1.49%
Shares Change (QoQ)	0.51%
Owned by Institutions (%)	78.83%
Shares Floating	93.24M
Failed to Deliver (FTD) Shares	10
FTD / Avg. Volume	n/a

Short Selling Information

The latest short interest is 11.22M, so 10.58% of the outstanding shares have been sold short.

Short Interest	11.22M
Short % of Shares Out	10.58%
Short % of Float	14.27%
Short Ratio (days to cover)	10.7

Valuation Ratios

The PE ratio is 37.23 and the forward PE ratio is 33.14. Corcept Therapeutics's PEG ratio is 1.15.

PE Ratio	37.23
Forward PE	33.14
PS Ratio	7.71
Forward PS	6.1
PB Ratio	7.65
P/FCF Ratio	26.55
PEG Ratio	1.15

Financial Ratio History

Enterprise Valuation

Corcept Therapeutics has an Enterprise Value (EV) of 5.08B.

EV / Sales	7.53
EV / EBITDA	37.1
EV / EBIT	25.65
EV / FCF	25.94

Financial Position

The company has a current ratio of 3.35, with a Debt / Equity ratio of 0.01.

Current Ratio	3.35
Quick Ratio	3.26
Debt / Equity	0.01
Debt / EBITDA	0.05
Debt / FCF	0.04
Interest Coverage	0

Financial Efficiency

Return on Equity is 20.56% and Return on Invested Capital is 17.09%.

Return on Equity	20.56%
Return on Assets	16.62%
Return on Invested Capital	17.09%
Revenue Per Employee	$1.35M
Profits Per Employee	$279.47K
Employee Count	500
Asset Turnover	0.8
Inventory Turnover	0.88

Taxes

Income Tax	20.28M
Effective Tax Rate	12.56%

Stock Price Statistics

The stock price has increased by 110.94% in the last 52 weeks. The beta is 0.2, so Corcept Therapeutics's price volatility has been higher than the market average.

Beta	0.2
52-Week Price Change	110.94%
50-Day Moving Average	71.19
200-Day Moving Average	64.11
Relative Strength Index (RSI)	55.16
Average Volume (20 Days)	1,288,558

Income Statement

In the last 12 months, Corcept Therapeutics had revenue of 675.04M and earned 139.73M in profits. Earnings per share was 1.35.

Revenue	675.04M
Gross Profit	664.16M
Operating Income	136.95M
Net Income	139.73M
EBITDA	136.95M
EBIT	136.95M
Earnings Per Share (EPS)	1.35

Full Income Statement

Balance Sheet

The company has 127.67M in cash and 6.94M in debt, giving a net cash position of 120.73M.

Cash & Cash Equivalents	127.67M
Total Debt	6.94M
Net Cash	120.73M
Retained Earnings	543.74M
Total Assets	801.72M
Working Capital	298.45M

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was 198.07M and capital expenditures -2.17M, giving a free cash flow of 195.9M.

Operating Cash Flow	198.07M
Capital Expenditures	-2.17M
Free Cash Flow	195.9M
FCF Per Share	1.9

Full Cash Flow Statement

Margins

Gross margin is 98.39%, with operating and profit margins of 20.29% and 20.7%.

Gross Margin	98.39%
Operating Margin	20.29%
Pretax Margin	23.92%
Profit Margin	20.7%
EBITDA Margin	20.29%
EBIT Margin	20.29%
FCF Margin	29.02%

Dividends & Yields

CORT does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Payout Ratio	n/a
Earnings Yield	2.69%
FCF Yield	3.77%

Dividend Details

Analyst Forecast

The average price target for CORT is $141, which is 96% higher than the current price. The consensus rating is "Buy".

Price Target	$141
Price Target Difference	96%
Analyst Consensus	Buy
Analyst Count	4

Stock Forecasts

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	$10.76
Lynch Upside	-85.05%
Graham Number	14.16
Graham Upside	-80.32%

Scores

Altman Z-Score	30.04
Piotroski F-Score	4